Biogen walks away from Sage's essential tremor drug after mid-stage flop, pill's future in question
Biogen is saying goodbye to part of its tie-up with Sage Therapeutics after the duo’s experimental medicine failed a Phase 2 essential …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
